Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 7/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13253683 | 0.84 | PLK1 (0.50) | PLK1HDAC6HDAC2HDAC8HPGD | |
| SCHEMBL10294735 | 0.82 | PLK1 (0.56) | PLK1HDAC6HDAC2HDAC8HPGD | |
| SCHEMBL8975652 | 0.82 | HPGD (0.57) | L3MBTL1HPGDHTTSMN1; SMN2TNIK | |
| SCHEMBL1663690 | 0.80 | L3MBTL1 (0.58) | L3MBTL1HPGDTSHRSMN1; SMN2CA12 | |
| SCHEMBL1665050 | 0.80 | RAB9A (0.53) | L3MBTL1TSHRHTTSMN1; SMN2TNIK | |
| SCHEMBL16016477 | 0.79 | L3MBTL1 (0.53) | L3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL21254607 | 0.78 | TNIK (0.47) | L3MBTL1TSHRHTTSMN1; SMN2TNIK | |
| SCHEMBL2567664 | 0.77 | GAA (0.66) | PLK1HDAC6HDAC2HDAC8HPGD | |
| SCHEMBL8773483 | 0.76 | KDM4E (0.54) | L3MBTL1TSHRSMN1; SMN2HDAC1TNIK | |
| SCHEMBL21082729 | 0.76 | L3MBTL1 (0.66) | L3MBTL1HPGDSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | L3MBTL1 1818/4885PLK1 1390/4885HDAC6 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.